BNP Paribas Asset Management
LAB icon

BNP Paribas Asset Management’s Standard BioTools LAB Stock Holding History

BNP Paribas Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,037
Closed -$9.23K – 2305
2026
Q1 		$9.23K Buy
10,037
+3,373
+51% +$4.08K ﹤0.01% 2234
2025
Q4 		$9K Buy
6,664
+1,964
+42% +$2.64K ﹤0.01% 2173
2025
Q3 		$6K Hold
4,700
– – ﹤0.01% 1776
2025
Q2 		$6K Buy
+4,700
New +$5.21K ﹤0.01% 1939

Other funds holding LAB

Casdin Capital
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MAK Capital One
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Hollow Brook Wealth Management
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BNP Paribas Asset Management's LAB Position: Q2 2026 in Review

BNP Paribas Asset Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 10,037 shares — an estimated $9.23K sold.

BNP Paribas Asset Management first reported a position in LAB in Q2 2025 and held it in 4 quarters. The position peaked at $9.23K in Q1 2026. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • BNP Paribas Asset Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 10,037 Standard BioTools shares in Q2 2026, an estimated $9.23K.
  • BNP Paribas Asset Management first reported a position in Standard BioTools in Q2 2025 and held it in 4 quarters.
  • BNP Paribas Asset Management's Standard BioTools position peaked at $9.23K in Q1 2026.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.